Università degli Studi di Siena Trials

Università degli Studi di Siena	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Dotta, Francesco

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

09/25

01/26

Ver-A-T1D, NCT04545151 / 2020-000435-45: Verapamil SR in Adults With Type 1 Diabetes

Active, not recruiting

138

Europe

Verapamil SR 120 mg, VeraHEXAL KHK 120 mg, Isoptin retard 120 mg, Placebo, Matching Placebo for Verapamil SR 120 mg

Medical University of Graz, Juvenile Diabetes Research Foundation

Diabetes Mellitus, Type 1

05/25

05/26

INNODIA, NCT03936634: An Innovative Approach Towards Understanding and Arresting Type 1 Diabetes

Recruiting

N/A

6000

Europe

University of Cambridge, Innovative Medicines Initiative, Juvenile Diabetes Research Foundation, The Leona M. and Harry B. Helmsley Charitable Trust

Type 1 Diabetes Mellitus

10/22

Ludvik, Bernhard

COMBAT_T2_NASH, NCT04639414: Combined Active Treatment in Type 2 Diabetes with NASH

Active, not recruiting

192

Europe

Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector, Jardiance(R), Ozempic(R), Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide, Jardiance(R), Placebo matching empagliflozin and placebo pen injector matching semaglutide, Control / Placebo

German Diabetes Center, Boehringer Ingelheim, German Center for Diabetes Research, Federal Ministry of Health, Germany, Ministry of Innovation, Science and Research in North Rhine-Westphalia, Novo Nordisk A/S

Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD)

01/25

12/25

NCT02817360: NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

Recruiting

2400

Europe, RoW

RAS-antagonist and beta-blocker up-to maximal dosages, Enalapril 40mg/d, Ramipril 10mg/d, Lisinopril 40mg/d, Cilazapril 5mg/d, Perindopril 8mg/d, Captopril 150mg/d, Spirapril 24mg/d, Quinapril 40mg/d, Trandolapril 4mg/d, Zofenopril 60mg/d, Fosinopril 40mg/d, Candesartan 32mg/d, Valsartan 320mg/d, Irbesartan 300mg/d, Losartan 150mg/d, Eprosartan 800mg/d, Bisoprolol 10mg/d, Metoprololsuccinat 200mg/d, Carvedilol 50mg/d (100mg/d if weight is > 85kg), Nebivolol 10mg/d, RAS-antagonist and beta-blocker none or at stable dose

Martin Huelsmann

Heart Diseases, Diabetes Mellitus, Type 2

12/25

12/26

NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting

12500

Europe, Canada, Japan, US, RoW

Lepodisiran Sodium, LY3819469, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

03/29

NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting

10000

Europe, Canada, US, RoW

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

02/29

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

09/25

01/26

SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting

15374

Europe, Canada, Japan, US, RoW

Tirzepatide, LY3298176, Placebo

Eli Lilly and Company

Obesity, Overweight

10/27

Ver-A-T1D, NCT04545151 / 2020-000435-45: Verapamil SR in Adults With Type 1 Diabetes

Active, not recruiting

138

Europe

Verapamil SR 120 mg, VeraHEXAL KHK 120 mg, Isoptin retard 120 mg, Placebo, Matching Placebo for Verapamil SR 120 mg

Medical University of Graz, Juvenile Diabetes Research Foundation

Diabetes Mellitus, Type 1

05/25

05/26

TREASURE-CKD, NCT05536804 / 2021-005273-47: A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Recruiting

140

Europe, Canada, US, RoW

Tirzepatide, Placebo

Eli Lilly and Company, Eli Lilly and Company

Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D

01/26

02/26

Fagiolini, Andrea

OPADE, NCT06550037: Optimize and Predict Antidepressant Efficacy for Patient With MDD Using Multi-omics Analysis and AI-predictive Tool

Recruiting

N/A

350

Europe

Alessio Fasano, University of Siena, Fundació Eurecat, Perseus Biomics, ARTIFICIAL INTELLIGENCE EXPERT SRL, Mama Health Technologies GmbH, Protobios OU, Cephalgo, Biokeralty Research Institute, Sanitas University, Accare, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Istanbul Medipol University Hospital, CEINGE, Fondazione di ricerca biomedica EBRIS

Major Depressive Disorder

08/25

05/27

Hamouda, Aicha

Ver-A-T1D, NCT04545151 / 2020-000435-45: Verapamil SR in Adults With Type 1 Diabetes

Active, not recruiting

138

Europe

Verapamil SR 120 mg, VeraHEXAL KHK 120 mg, Isoptin retard 120 mg, Placebo, Matching Placebo for Verapamil SR 120 mg

Medical University of Graz, Juvenile Diabetes Research Foundation

Diabetes Mellitus, Type 1

05/25

05/26

Formichi, Caterina

Ver-A-T1D, NCT04545151 / 2020-000435-45: Verapamil SR in Adults With Type 1 Diabetes

Active, not recruiting

138

Europe

Verapamil SR 120 mg, VeraHEXAL KHK 120 mg, Isoptin retard 120 mg, Placebo, Matching Placebo for Verapamil SR 120 mg

Medical University of Graz, Juvenile Diabetes Research Foundation

Diabetes Mellitus, Type 1

05/25

05/26

Renieri, Alessandra

GEN-COVID, NCT04549831: Genetic Bases of COVID-19 Clinical Variability

Recruiting

N/A

2000

Europe

Massive parallel sequencing of host genome

University of Siena, Fondazione IRCCS Policlinico San Matteo di Pavia, Ospedale San Donato, Arezzo, Ospedale della Misericordia, Azienda Ospedaliera Ospedale Maggiore di Crema, University of Modena and Reggio Emilia, ASST Fatebenefratelli Sacco, Azienda Ospedaliera di Perugia, Ospedale dell'Angelo, Venezia-Mestre, Azienda Ulss 2 Marca Trevigiana, Cardarelli Hospital, Azienda Ospedaliera dei Colli, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Istituto Giannina Gaslini, Istituti Ospitalieri di Cremona, IRCSS Lazzaro Spallanzani, Roma, ASST Santi Paolo e Carlo, ASST Valtellina e Alto Lario, Azienda USL Toscana Sud Est, ULSS1 Dolomiti, Belluno, ASST Spedali Civili, Brescia, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Ospedale Luigi Curto, Polla, Istituto Auxologico Italiano, CEINGE Biotecnologie Avanzate, Napoli

COVID-19

12/22

04/26

SCREEN4CARE, NCT06549218: Genetic Newborn Screening for Rare Diseases Within the Screen4Care Project

Recruiting

N/A

20000

Europe

newborn genetic screening and whole genome sequencing

University Hospital Freiburg, Innovative Medicines Initiative, Università degli Studi di Ferrara, Ospedale Pediatrico Bambin Gesù, University of Siena, Centre Hospitalier Universitaire Dijon, Real Genix, University Hospital Erlangen, University Hospital Goettingen, Centro Nacional de Análisis Genómico, Genoox

Newborn Screening

12/25

Cameli, Matteo

RICMAF, NCT06806813: Italian Anderson Fabry Disease Cardiovascular Registry

Recruiting

N/A

800

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Fabry Disease

01/31

12/31

FUTURE-HIT, NCT05204238: Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)

Active, not recruiting

N/A

998

Europe, RoW

Transthoracic Echocardiography

University of Siena, European Association of Cardiovascular Imaging

Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Reduced Ejection Fraction

07/22

11/22

AT-TARGET-IT, NCT05430828: Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy

Recruiting

N/A

2000

Europe

Repatha (evolocumab); Praluent (alirocumab)

Federico II University

Hypercholesterolemia

03/24

DISCOVERSGLT2i, NCT05344963: Deformation Imaging by Strain in Chronic Heart Failure Over Gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 Inhibitors

Completed

N/A

503

Europe

Sodium-GLucose coTransporter-2 inhibitors

Matteo Cameli, Fondazione Toscana G. Monasterio, Pisa, University Of Perugia, Section of Cardiology, Department of Medicine, University of Verona, Verona, Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, Cardiology and Arrhythmology Clinic, Marche Polytechnic University, 60121 Ancona, Cardiology Department, Ospedale Guglielmo da Saliceto - Piacenza, University Cardiology Unit, Cardiothoracic Department, Polyclinic University Hospital, Bari, ProMISE, University Hospital Paolo Giaccone, University of Palermo, Department of Cardiovascular Disease - AUSL Romagna, Division of Cardiology, Ospedale S. Maria Delle Croci, Viale Randi 5, 48121, Ravenna, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Department of Biomedical Sciences for Health, University of Milano, Milan, Division, of Cardiology, 'A. De Gasperis' Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore 3, 20162, Milan, Department of Advanced Biomedical Science, Federico II University Hospital, Naples, Department of Thoracic, Heart and Vascular Diseases, Maggiore della Carità Hospital, Novara, Divisione di Cardiologia, Ospedale S. Maria del Carmine, Rovereto, TN, ASST-Rhodense; Ospedale di Circolo di Rho, Cardio-Thoracic-Vascular Department. University Hospital San Giovanni di Dio e Ruggi d'Aragona. Salerno, Centro Medico Sant'Agostino, Milano, Università Politecnica delle Marche, Ospedali riuniti di Ancona, Department of Cardiology, Policlinico Universitario Campus Bio-Medico, Via Álvaro del Portillo, 21, Roma

Sodium-GLucose coTransporter-2 Inhibitors, Heart Failure With Reduced Ejection Fraction

05/24

06/24

rEPORt, NCT05753553: Incidence and Echocardiographic Predictors of HFpEF in High-Risk Population Afferent to Italian Echo-labs Network

Recruiting

N/A

1000

Europe

IRCCS Policlinico S. Donato

Heart Failure, Heart Failure With Preserved Ejection Fraction

06/25

07/25



	Diseases Companies Products Productz Mechanisms of Action Sites